DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Pirarubicin is an investigational drug.
There have been 20 clinical trials for Pirarubicin. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2012.
The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Transitional Cell, and Recurrence. The leading clinical trial sponsors are Peking University People's Hospital, Sun Yat-sen University, and Peking Union Medical College Hospital.
There are two US patents protecting this investigational drug and twenty-eight international patents.
Recent Clinical Trials for Pirarubicin
|Combination Therapy of Anthracyclines for Children With Nephroblastoma||Shengjing Hospital||Phase 4|
|Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma||Tianjin Medical University Cancer Institute and Hospital||Phase 2|
|Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma||Beijing Jishuitan Hospital||Phase 2/Phase 3|
Top disease conditions for Pirarubicin
Top clinical trial sponsors for Pirarubicin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Pirarubicin||Start Trial||Heat shock protein 70 (hsp-70) receptor ligands||Duke University (Durham, NC)||Start Trial|
|Pirarubicin||Start Trial||Compounds and their methods of use||Agios Pharmaceuticals, Inc. (Cambridge, MA)||Start Trial|
|Pirarubicin||Start Trial||Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus||Seattle Genetics, Inc. (Bothell, WA)||Start Trial|
|Pirarubicin||Start Trial||Anti-FGFR3 antibodies and methods using same||Genentech, Inc. (South San Francisco, CA)||Start Trial|
|Pirarubicin||Start Trial||Bispecific antigen-binding constructs targeting HER2||Zymeworks Inc. (Vancouver, CA)||Start Trial|
|Pirarubicin||Start Trial||Method of diagnosing and treating cancer using B-catenin splice variants||The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Pirarubicin||World Intellectual Property Organization (WIPO)||2015148714||2034-03-25||Start Trial|
|Pirarubicin||Eurasian Patent Organization||201691896||2034-03-21||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|